Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy

PD-1/PD-L1 blockade therapy that eliminates T-cell inhibition signals is successful, but poor benefits are often observed. Increasing T-cell infiltration and quantity of PD-1/PD-L1 inhibitors in tumor can improve efficacy but remains challenging. Here, we devise tumor-specific gene nanomedicines to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yue, Zhou, Shi-Kun, Wang, Yan, Lu, Zi-Dong, Zhang, Yue, Xu, Cong-Fei, Wang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082825/
https://www.ncbi.nlm.nih.gov/pubmed/37031188
http://dx.doi.org/10.1038/s41467-023-37656-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082825/
https://www.ncbi.nlm.nih.gov/pubmed/37031188
http://dx.doi.org/10.1038/s41467-023-37656-w

Ejemplares similares